Tampa, Fla. (March 30, 2005) - Nanobac Life Sciences, Inc. (OTCBB: NNBP) (“Nanobac” or “the Company”) today announced the promotion of Grant D. Carlson from Vice President, Business Development to President and Chief Operating Officer effective immediately. Mr. Carlson will now have day-to-day operational responsibility for Nanobac’s in vitro diagnostics, dietary supplement, and drug discovery businesses.
"I am truly excited to have Grant Carlson assume the role of President and COO”, commented John Stanton, “Mr. Carlson has been instrumental in driving the scientific and strategic direction of the Company. He has a long-standing track record of success in marketing innovative technology and has a skill set that will complement the needs of Nanobac and allow him to effectively lead the company to the next level.”
Mr. Carlson has extensive expertise in general management, corporate and business development, product development, product launch, and sales and marketing.
Prior to joining Nanobac, Mr. Carlson was vice president of marketing and business development at Agilix Corporation, a functional genomics company developing gene expression and protein profiling technologies for biotechnology and pharmaceutical customers.
Prior to Agilix in 2001, Mr. Carlson served as vice president of marketing and business development for Dianon Systems, Inc., a leading cancer and genomic diagnostic services company. Dianon Systems was acquired by LabCorp for $598 million. During his 13 years at Dianon, Mr. Carlson held senior positions in research and development, marketing, business development, technology development and sales. Under Mr. Carlson’s leadership, Dianon launched over 50 advanced diagnostic products and biomarkers into clinical practice. He is co-inventor on five U.S. patents involving free-PSA and the diagnosis of prostate cancer. He has authored several scientific papers in the areas of oncology, urology and diagnostic pathology. He holds a B.S. in Kinesiology from the University of California, Los Angeles.
“We look forward working with Mr. Carlson as he leads the Company to the next level,” added Board member, Alex H. Edwards, III. “Mr. Carlson brings a wealth of leadership experience that will be essential to Nanobac's future success as we strive to continue to create value for our shareholders."
Nanobac Life Sciences, Inc. is dedicated to improving people’s health through the detection and eradication of Nanobacterium sanguineum (Nanobacteria). The Company’s pioneering research is establishing the pathogenic role of Nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2™ ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to treat nanobacterial infection. The Company currently markets a patented nanobiotic regimen. For further information concerning our nanobiotic, please visit http://www.nanobacsciences.com.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.